歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01672 歌礼制药-B

交易中 09-25 10:54:49

8.555

-0.200

-2.28%

最高8.755	最低8.530	成交量17.90万
今开8.755	昨收8.755	日振幅2.57%
总市值90.00亿	流通市值90.00亿	总股本10.52亿
成交额153.44万	换手率0.02%	流通股本10.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"歌礼制药-B","latestPrice":8.555,"timestamp":1790304363153,"preClose":8.755,"halted":0,"volume":179000,"delay":0,"changeRate":-0.02284408909194758,"floatShares":1052000000,"shares":1052000000,"eps":-0.43209298376343247,"marketStatus":"交易中","change":-0.2,"latestTime":"09-25 10:54:49","open":8.755,"high":8.755,"low":8.53,"amount":1534365,"amplitude":0.0257,"askPrice":8.555,"askSize":13000,"bidPrice":8.54,"bidSize":16000,"shortable":3,"etf":0,"ttmEps":-0.6829509225429446,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1790308800000},"marketStatusCode":2,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":8.755,"openAndCloseTimeList":[[1790299800000,1790308800000],[1790312400000,1790323200000]],"volumeRatio":0.298592,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672","defaultTab":"news","newsList":[{"id":"1188227323","title":"创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188227323","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188227323?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:01","pubTimestamp":1790132509,"startTime":"0","endTime":"0","summary":"9月23日，创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%，康方生物、诺诚健华涨逾3%，基石药业涨逾2%，百济神州、药明生物、君实生物涨逾1%，信达生物跟涨。9月12-15日2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3 ADC等成为焦点；与此同时，2026年国家医保目录谈判收官，商保创新药目录同步推进，支付端改革预期升温，\"出海商业化+支付改善\"的产业逻辑持续强化。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","02269","03347","02359","03759","06622","06978","06996","00241","09606","09688","09966","06606","09995","02137","06618","02268","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919445","title":"港股异动 | 生物医药股悉数走高 十部门印发医药十五五规划 机构看好医药迎“Claude”时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919445","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668919445?lang=zh_cn&edition=full","pubTime":"2026-09-18 10:04","pubTimestamp":1789697085,"startTime":"0","endTime":"0","summary":"消息面上，工信部等十部门联合发布《医药工业发展\"十五五\"规划》，提出到2030年的发展目标：生物医药研发应用稳居世界前列，创新驱动效能充分释放，重点领域关键核心技术实现系统性突破，生物医药产业加速成为国家新兴支柱产业。浙商证券表示，高频迭代短期将会带来验证阶段需求的井喷，但长期来看，高速迭代可能会带来平台能力的提升和泛化，能够持续迭代的发现平台能力提升或是行业的核心，医药行业的Claude也许将要到来。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","XBI","BK1574","BK4581","BK1141","VXUS","09939","399441","159938","09688","02142","BK4585","01672","BK1161","161726","06127","KCAI","BK1588","07666","LU2488822045.USD","BK1583","BK1576","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666597825","title":"歌礼制药-B盘初涨近5% 公司启动ASC36口服片美国I期肥胖症研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2666597825","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666597825?lang=zh_cn&edition=full","pubTime":"2026-09-10 09:40","pubTimestamp":1789004400,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端歌礼制药-B（01672）盘初涨近5%。截至发稿，涨幅回落，微涨0.50%，报10.11港元，成交额181.76万港元。歌礼制药宣布，在近期获得美国食品药品监督管理局（FDA）批准新药临床试验（IND）后，其已启动ASC36口服片（口服胰淀素受体激动剂多肽）用于治疗肥胖症的美国I期研究。歌礼创始人、董事会主席兼首席执行官吴劲梓博士表示，2026年，我们就多肽管线启动了四项I期研究，ASC36口服片是其中第四项也是最新的一项，这是歌礼多肽管线的一项重要里程碑，也进一步验证了我们专有的POTENT口服多肽递送技术。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-10/doc-iniriafa7893825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","BK1191","BK1574","01672","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666559944","title":"港股异动 | 歌礼制药-B(01672.HK)早盘涨近5% 公司启动ASC36口服片美国I期肥胖症研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2666559944","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666559944?lang=zh_cn&edition=full","pubTime":"2026-09-10 09:27","pubTimestamp":1789003653,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1161","01477","BK1574","01672","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185189845","title":"歌礼制药-B（01672）获美FDA批准启动ASC36口服片治疗肥胖症I期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=1185189845","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185189845?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:12","pubTimestamp":1788862324,"startTime":"0","endTime":"0","summary":"2026年9月8日，歌礼制药-B公告称，其自主研发的口服胰淀素受体激动剂多肽ASC36已获美国食品药品监督管理局新药临床试验批准，并在美国启动I期临床研究。公司表示，基于6%至8%的口服生物利用度和观察到的减重效果，预计ASC36口服片所需剂量将低于近期获FDA批准的某GLP-1R激动剂多肽，且每毫克的减重效率可能带来规模化生产成本优势。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665503321","title":"歌礼制药-B(01672)在美国启动口服胰淀素受体激动剂多肽ASC36 治疗肥胖症的I期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2665503321","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665503321?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:04","pubTimestamp":1788861852,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，在近期获得美国食品药品监督管理局 批准新药临床试验后，其已启动ASC36口服片用于治疗肥胖症的美国I期研究。在非人灵长类动物中，ASC36口服片每日一次给药7天后，使平均体重相较基线下降高达13.2%。ASC36片亦显著减少了食物摄入。基于潜在更优的口服生物利用度和疗效，与近期获FDA批准的一款GLP-1R激动剂多肽相比，预计ASC36口服片的给药剂量更低。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1574","01477","BK1515","BK1161","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665394527","title":"港股异动 | 歌礼制药-B(01672.HK)午后涨超6% 公司正式进入港股通名单  ASC30近期完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2665394527","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665394527?lang=zh_cn&edition=full","pubTime":"2026-09-07 14:15","pubTimestamp":1788761745,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1161","01672","BK1574","BK1515","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665399941","title":"歌礼制药纳入港股通 今日正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2665399941","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665399941?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:25","pubTimestamp":1788755100,"startTime":"0","endTime":"0","summary":"歌礼制药（01672）发布公告，公司于2026年9月7日起，获纳入沪港通及深港通计划下的港股通名单。此次纳入将使符合相关资格的国内投资者能够通过港股通渠道交易公司股票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866532228.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866532228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1515","FLHK","BK1574","01477","01672","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164090375","title":"歌礼制药-B获纳入沪深港通下港股通名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1164090375","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164090375?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:18","pubTimestamp":1788754680,"startTime":"0","endTime":"0","summary":"歌礼制药-B（Ascletis-B）宣布，公司已成功入选港股通名单，该名单适用于上海-香港股票市场交易互联互通机制以及深圳-香港股票市场交易互联互通机制。这一里程碑式的进展，标志着公司股票正式进入沪深港通体系，为两地投资者提供了更为便捷的投资通道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1515","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665352399","title":"歌礼制药-B(01672.HK)获纳入沪港通及深港通计划项下的港股通名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2665352399","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665352399?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:16","pubTimestamp":1788754601,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01477","BK1191","BK1574","01672","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137554221","title":"歌礼制药-B（01672）获纳入沪港通及深港通合资格证券名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1137554221","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137554221?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:06","pubTimestamp":1788753995,"startTime":"0","endTime":"0","summary":"2026年9月7日，歌礼制药-B（01672）公告称，其在香港联合交易所有限公司上市的普通股将被纳入沪港通及深港通（统称“港股通”）机制的合资格证券名单，并自同日正式生效。\n根据公告，在纳入名单后，符合相关资格的中国内地投资者可通过沪港通及深港通渠道买卖歌礼制药-B的股份。公司表示，此次纳入反映市场对其投资价值及成长前景的认可，并有望带来更广泛的股东基础及提升股份流通性。\n沪港通及深港通是连接中国内地与香港资本市场的互联互通机制，由上海证券交易所、深圳证券交易所与香港联合交易所共同运营，为两地投资者提供跨境买卖对方市场合资格股票的渠道。\n公司提醒股东及潜在投资者于买卖其股份时保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665930583","title":"深交所：将歌礼制药(01672)、曦智科技(01879)等调入深港通下的港股通标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2665930583","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665930583?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:57","pubTimestamp":1788746223,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，9月7日，深交所公告，根据《深圳证券交易所深港通业务实施办法》的有关规定，港股通标的证券名单发生调整并自2026年09月07日起生效。调入歌礼制药(01672)、曦智科技(01879)、百度集团(09888)等，调出日清食品(01475)、海昌海洋公园(02255)、狮腾控股(02562)等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260907/32361455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["FLHK","BK1191","BK1515","BK1161","BK1574","01879","BK1163","01672","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664233915","title":"上交所宣布调整沪港通下港股通标的，调入百度、歌礼制药等54只，调出佑驾创新等15只。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664233915","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664233915?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:33","pubTimestamp":1788521612,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000306685.HKD","LU0359202008.SGD","LU0417516738.SGD","LU0762541174.USD","BK1588","BK1615","LU0052750758.USD","LU0417516902.SGD","LU0326950275.SGD","BK1575","LU0348825331.USD","LU0463099449.HKD","LU0315179316.USD","09888","LU0039217434.USD","LU2476274308.USD","LU1481107354.HKD","IE00B3M56506.USD","HK0000320223.HKD","02431","HK0000320264.USD","LU0197773160.USD","BK1095","LU0823426308.USD","LU0708995583.HKD","LU0543330566.HKD","LU0456827905.SGD","LU0149721374.USD","LU2778985437.USD","BK1609","LU0173614495.USD","LU0871576103.HKD","LU1188198961.HKD","89888","BK1515","LU0640798160.USD","SG9999014674.SGD","SG9999002463.SGD","LU0307460666.USD","BK1587","BK1144","LU1048596156.SGD","LU0043850808.USD","LU0287142896.SGD","LU2039709279.SGD","TCHI","LU0348735423.USD","LU0228367735.SGD","LU1023057109.AUD","BK1574","LU0630378429.USD","LU1048588211.SGD","IE0034224299.USD","LU0630378692.HKD","LU0819121731.USD","LU0359201885.HKD","BIDU","LU0359201612.USD","BK1161","LU0821914370.USD","LU0229945570.USD","SG9999002828.SGD","LU0762540952.USD","LU0762542818.HKD","LU0051755006.USD","LU0197773673.USD","LU0163747925.USD","HK0000306701.USD","LU0244354667.USD","LU0072462343.USD","LU1328615791.USD","LU0588546209.SGD","LU0164880469.USD","LU1831875114.USD","LU0856984785.SGD","LU1115378108.SGD","LU0831093199.SGD","LU0164865239.USD","LU0531971595.HKD","LU0320764599.SGD","LU0823426480.USD","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664014829","title":"大行评级丨高盛：下调歌礼制药目标价至13.86港元，维持“中性”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664014829","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664014829?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:04","pubTimestamp":1788415446,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["01477","BK1515","BK1191","BK1574","BK1161","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112769612","title":"歌礼制药-B更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1112769612","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112769612?lang=zh_cn&edition=full","pubTime":"2026-09-03 10:36","pubTimestamp":1788402967,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年9月3日披露了截至2026年8月31日止的证券变动月报表。公告显示，公司法定/注册股本无变化，仍为70亿股普通股，面值每股0.0001美元，法定/注册股本总额700,000美元。报告期末，公司已发行普通股总数为1,051,984,845股，库存股为5,784,210股，与上月底一致。歌礼制药-B于本报告期内继续符合香港联交所对公众持股量的相关规定。截至8月末，公司整体股本结构保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664898526","title":"歌礼制药-B早盘涨超8% ASC30用于长期体重管理的全球III期临床项目完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2664898526","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664898526?lang=zh_cn&edition=full","pubTime":"2026-09-02 10:13","pubTimestamp":1788315180,"startTime":"0","endTime":"0","summary":"模拟交易客户端歌礼制药-B早盘涨超8%，截至发稿，股价上涨8.07%，现报10.31港元，成交额926.46万港元。近日，歌礼制药-B发布公告，ASC30用于长期体重管理的全球III期临床项目已完成首例受试者给药。ASC30是一款歌礼专有的、正在临床研究中的每日一次口服小分子胰高血糖素样肽-1受体激动剂，开发用于长期体重管理和糖尿病治疗。公告称，歌礼制药-B预计将于2028年第三季度公布AURORA III期临床项目的顶线数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-02/doc-iniqkzma1311603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1191","BK1161","BK1574","01477","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664260860","title":"港股异动 | 歌礼制药-B(01672.HK)涨超5% ASC30用于长期体重管理的全球III期临床项目完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2664260860","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664260860?lang=zh_cn&edition=full","pubTime":"2026-09-02 09:49","pubTimestamp":1788313757,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","01672","BK1161","BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006583","title":"歌礼制药-B(01672)发布中期业绩 股东应占亏损3.2亿元 同比增加263.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006583","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663006583?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:24","pubTimestamp":1788182651,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布截至2026年6月30日止六个月业绩，该集团取得收入总额人民币5297.9万元，同比减少48.9%;研发成本3.42亿元，同比增加132.7%;公司权益股东应占亏损3.2亿元，同比增加263.5%;每股亏损30.74分。人体数据表明，ASC50有望成为同类首创及同类最佳口服小分子IL-17A抑制剂。ASC51为一款强效、选择性及每日一次口服STAT6降解剂并已具备向FDA 提交IND申请条件的候选药物。ASC52有望成为同类最佳IL-17AA、AF及FF口服环肽拮抗剂，预计将于2026年第四季度向FDA递交IND。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1191","BK1161","BK1574","01477","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162031632","title":"歌礼制药-B：董事会建议不派发中期股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1162031632","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162031632?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:18","pubTimestamp":1788182334,"startTime":"0","endTime":"0","summary":"歌礼制药-B（01672.HK）宣布，其董事会已决定不建议就中期业绩派发任何股息。这一决定反映出公司在当前阶段的财务策略与资本配置考量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","01672","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118188053","title":"歌礼制药-B2026年中期财报营收5,298万元，经调整净亏损3.20亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118188053","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118188053?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:17","pubTimestamp":1788182270,"startTime":"0","endTime":"0","summary":"本季度信息\n据公司公告披露，歌礼制药-B在截至2026年6月30日止六个月实现营收5,298万元，同比下降48.9%。经调整净亏损为3.20亿元，同比扩大263.5%。\n公告显示，研发成本约3.42亿元，同比大幅增长132.7%，主要系公司加大在代谢性疾病相关管线的投入。行政开支约3,080.3万元，同比下降28.9%，主要来自员工相关成本的减少。公司未在公告中披露具体毛利率及经营利润率，但经营成本结构显示，研发投入占比在报告期内进一步上升。\n此外，期内经营活动所用现金净额约3.27亿元，账面现金及现金等价物等共约23.05亿元，可支持公司运营至2029年。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"歌礼制药-B2026年中期财报营收5,298万元，经调整净亏损3.20亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":0.0749},{"period":"1month","weight":-0.1134},{"period":"3month","weight":-0.0993},{"period":"6month","weight":-0.4807},{"period":"1year","weight":-0.236},{"period":"ytd","weight":-0.2313}],"compareEarnings":[{"period":"1week","weight":0.0064},{"period":"1month","weight":-0.0294},{"period":"3month","weight":0.0922},{"period":"6month","weight":-0.0076},{"period":"1year","weight":-0.0663},{"period":"ytd","weight":-0.0339}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"歌礼制药有限公司是一家主要从事医药产品研发、生产和销售的投资控股公司。该公司专注于病毒性疾病、非酒精性脂肪性肝炎（NASH）或原发性胆汁性胆管炎（PBC）及肿瘤领域。该公司的产品管线包括用于慢性乙肝功能性治愈的ASC22、用于呼吸道合胞病毒（RSV）的ASC10、用于人类免疫缺陷病毒（HIV）功能性治愈的ASC22、用於新冠肺炎的ASC10及ASC11、用於NASH的ASC41、用於PBC的ASC42、用于实体瘤的ASC61、用于中、重度痤疮的ASC40等。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.146882},{"month":2,"riseRate":0.75,"avgChangeRate":0.100059},{"month":3,"riseRate":0.375,"avgChangeRate":-0.044472},{"month":4,"riseRate":0.375,"avgChangeRate":-0.053142},{"month":5,"riseRate":0.375,"avgChangeRate":-0.01034},{"month":6,"riseRate":0.375,"avgChangeRate":-0.053675},{"month":7,"riseRate":0.5,"avgChangeRate":0.001982},{"month":8,"riseRate":0.375,"avgChangeRate":-0.008209},{"month":9,"riseRate":0.111111,"avgChangeRate":-0.078887},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.087327}],"exchange":"SEHK","name":"歌礼制药-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"歌礼制药-B,01672,歌礼制药-B股票,歌礼制药-B股票老虎,歌礼制药-B股票老虎国际,歌礼制药-B行情,歌礼制药-B股票行情,歌礼制药-B股价,歌礼制药-B股市,歌礼制药-B股票价格,歌礼制药-B股票交易,歌礼制药-B股票购买,歌礼制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}